Real world study in Italian public hospital with Efgartigimod in patients affected by generalized myasthenia gravis: influence of clinical and serological factors
Our findings suggest that patients with high baseline AChR antibody titers, previous thymectomy, and non-ocular symptom predominance respond better to Efgartigimod. These results underscore the need for larger studies to validate these observations and optimize patient selection.
Authors
- Francesca Martorana (ORCID: https://orcid.org/0000-0003-4091-8134)
- Sergio Mazzoleni (ORCID: https://orcid.org/0000-0003-3781-2902)
- Manlio Sgarzi (ORCID: https://orcid.org/0000-0002-6875-8542)
- Giorgia Camera (ORCID: https://orcid.org/0009-0001-3361-9032)
- Emanuela Agazzi (ORCID: https://orcid.org/0009-0005-9505-2739)
- Dario Alimonti (ORCID: https://orcid.org/0000-0001-7964-6282)
- Paolo Paone (ORCID: https://orcid.org/0000-0002-1505-746X)
Institutions
- Ospedale Papa Giovanni XXIII (IT)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-05-07
- DOI
- https://doi.org/10.3389/fneur.2025.1555068
- Citations
- 2
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 2.78